All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Swiss drugmaker Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to Dec. 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.
All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
394.6 USD | -0.65% | -0.57% | 110B | ||
222.2 CHF | -3.27% | +0.95% | 196B | ||
100.8 CHF | -1.08% | +2.76% | 32.01B | ||
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |